Pyxis Oncology, Inc.
PYXSReported to SECin USCIK 0001782223Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 6. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Civik ThomasCEO & Chairman of the Board | Award | nothing paid2,503,050 shares | Sep 8, 2026 | Civik ThomasCEO & Chairman of the Board | nothing paid | Award | 2,503,050 | Sep 8, 2026 |
| Dupont Jakob— | Award | nothing paid46,000 shares | Aug 20, 2026 | Dupont Jakob | nothing paid | Award | 46,000 | Aug 20, 2026 |
| Civik ThomasInterim CEO | Award | nothing paid250,956 shares | Aug 14, 2026 | Civik ThomasInterim CEO | nothing paid | Award | 250,956 | Aug 14, 2026 |
| Dupont Jakob— | Option exercise | nothing paid35,000 shares | Jul 2, 2026 | Dupont Jakob | nothing paid | Option exercise | 35,000 | Jul 2, 2026 |
| Dupont Jakob— | Open-market sell | $107,10035,000 shares | Jul 2, 2026 | Dupont Jakob | $107,100 | Open-market sell | 35,000 | Jul 2, 2026 |